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Abstract 
The focus of this review is to summarise the known relationships between the expression of 
Heat Shock Protein 60 (Hsp60) and its association with the pathogenesis of Type 1 and 
Type 2 Diabetes Mellitus. Hsp60 is a mitochondrial stress protein that is induced by 
mitochondrial impairment. It is known to be secreted from a number of cell types and 
circulating levels have been documented in both Type 1 and 2 Diabetes mellitus patients. 
The biological significance of extracellular Hsp60 however, remains to be established. We 
will examine the links between Hsp60 and cellular anti and pro- inflammatory processes and 
specifically address how Hsp60 appears to affect immune inflammation by at least two 
different mechanisms: as a ligand for innate immune receptors and as an antigen recognized 
by adaptive immune receptors. We will also look at the role of Hsp60 during immune cell 
activation in atherosclerosis, a significant risk factor during the pathogenesis of Diabetes 
Mellitus. 
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Introduction 
Diabetes mellitus is a spectrum of metabolic disorders characterised by chronic 
hyperglycaemia and abnormalities within the metabolism of proteins, fats and carbohydrates 
(Polonsky 2012). The two most common form of diabetes are classified as Type 1 and 2. 
Type 1 also known as insulin-dependent diabetes (IDDM) is characterised by the 
autoimmune destruction of the β-cells of the pancreatic islets which ultimately results in loss 
of insulin production leading to hyperglycaemia (Roep & Tree, 2014). On the other hand, 
Type 2 diabetes is linked to disorders of both insulin secretion and insulin action (Olokoba, 
Obateru, & Olokoba, 2012). It is becoming increasingly clear that Type 2 diabetes is also 
associated with a progressive destruction of β-islet cells by autoimmune processes linked to 
inflammation (Itariu & Stulnig, 2014).  However, the key triggers and molecular mechanisms 
responsible for the loss of β-cells have not yet been elucidated. Since mitochondria play a 
key role in the secretion of insulin from β-islet cells (Maechler, 2013), in this review we will 
examine the role of the mitochondrial molecular stress protein Hsp60 in the pathogenesis of 
both Type 1 and 2 diabetes and the potential links between Hsp60 expression and 
inflammation. 
 
Role of mitochondrial Hsp60 in Type 1 & 2 Diabetes Mellitus 
Heat shock protein 60 (Hsp60) is a molecular stress protein predominantly localised to the 
mitochondrion where it is known to play a role in the folding of proteins in the mitochondrial 
matrix. Hsp60 is upregulated in response to mitochondrial impairment (Pellegrino, Nargund, 
& Haynes, 2013) and is considered to be an indicator of mitochondrial stress. Interestingly, 
Hsp60 has also been shown to be secreted from a variety of mammalian cell types (Gupta & 
Knowlton; Merendino et al., 2010; Swaroop, Sengupta, Suryawanshi, Adlakha, & Basu, 
2016) and is known to be found at elevated levels in both Type 1 and 2 Diabetes Mellitus 
(Jing Yuan, Peter Dunn, & Ryan Dennis Martinus, 2011). The physiological/pathological 
consequence of having elevated levels of Hsp60 in systemic circulation and the cell types 
responsible for secretion of Hsp60 into circulation in Diabetes Mellitus is not yet known.   
For many years Hsp60 has been observed in non-obese (NOD) mouse model of diabetes 
and has been linked to play a role in the destruction of pancreatic β-islet cells caused by the 
spontaneous development of autoimmune T-lymphocytes (Birk, Douek, et al., 1996). Several 
epitopes has been identified to have significant anti-Hsp60 T cells responses, but one in 
particular p277 peptide has shown the greatest anti-Hsp60 T cells responses (Abulafia-Lapid 
et al., 1999). The p277 peptide of Hsp60 has been widely studied over the years, it is 24 
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amino acid peptide within amino acid residue 427-460 derived from monocytes human 
Hsp60 (Elias et al., 1991). Hyperglycaemia and insulitis developed when standard strains of 
mice, not prone to spontaneous diabetes were immunized with p277 covalently conjugated 
to a foreign immunogenic carrier molecule (Elias, Marcus, Reshef, Ablamunits, & Cohen, 
1995).  
Interestingly, Hsp60 and p277 peptides can also lead to protection of β-cell functions (Raz et 
al., 2001; Sarikonda et al., 2015). This protection is thought to be due to modulation of the 
autoimmune process responsible for β- cell destruction. Therapeutic vaccination with p277 
has been documented to slow and inhibit the destruction of β-cells both in NOD mice and in 
humans. Administration of p277 has been shown to down regulate T-cell reactivity to β-cell 
antigens. This process is thought to be associated with a shift in cytokine profile from the 
pro-inflammatory T-helper 1 (Th1) phenotype to the anti-inflammatory T-helper-2 (Th2) 
phenotype. Thus, p277 has been shown to increase IL-4 and IL-10 secretion and a decrease 
in γ-IF secretion and is thought to be mediated by p277 binding to TLR2 receptors (Kim, Lee, 
Lee, Kim, & Lee, 2012; Nussbaum, Zanin-Zhorov, Quintana, Lider, & Cohen, 2006). 
Therefore, it is evident that Hsp60 is able to influence T-cell responses in two ways: as a 
ligand of toll-like receptor 2 signalling and as an antigen. But how can T-lymphocytes target 
Hsp60 (which is ubiquitous) and p227 epitope be involved with the destruction and 
protection of pancreatic β-cells?  One explanation for this is molecular mimicry. Hsp60 and 
p277 could possibly mimic a tissue specific antigen of the β-islet cells of the pancreas that 
has a p277 like epitope (Jones, Coulson, & Duff, 1993). A study by (Birk, Elias, et al., 1996) 
reported that mouse Hsp60 molecules in β-cells of NOD mouse is the target of anti-H-p277. 
However this finding poses the question of how a ubiquitous molecule such as Hsp60 can be 
the target of a tissue-specific autoimmune disease? There is no evidence to suggest that 
tissue-specific Hsp60 exist, given that there is a fibroblast homologue which contains 
identical sequence to the pancreatic β-islet Hsp60 (Birk, Elias, et al., 1996). However, 
several suggestions have been proposed in order to address this question; Hsp60 are 
present in a unique way in secretory vesicles of the β-cells, and in the event of insulin 
secretion, these vesicles fuse with the β-cell membrane causing Hsp60 to be presented on 
the β-cell membrane and/ or even secreted in the absence of mitochondrial stress, causing 
differences in secretion characteristic from other cells (Birk, Elias, et al., 1996; Brudzynski, 
Martinez, & Gupta, 1992). When C9 cells (a diabetogenic NOD T-cell clone that responds to 
p277) are injected into NOD mice, it migrates to the pancreas and kidney (Birk, Elias, et al., 
1996). Another experiment showed that there are 8-12 genes for Hsp60 in the vertebrate 
genome, however when sequenced, all but one was a pseudogene (Venner, Singh, & 
Gupta, 1990). All of these experiments suggest that although β-cell Hsp60 is not tissue 
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specific, there may be tissue specific post-translational modifications of Hsp60 (Birk, Elias, et 
al., 1996). Experiments have also shown how T-cells are still able to proliferate in the 
presence of β-cell and absence of other antigen-presenting cells suggesting that Hsp60 in β-
cell may be processed specifically to that tissue, enabling the β-cell to present its own Hsp60 
to the T-cells, and ultimately present specific immunogenic peptide like p277 (Birk, Elias, et 
al., 1996). Even though T-cells targets non-tissue specific molecules, it may have a greater 
preference over vulnerable, damaged β-cells, ultimately causing distress to β-cells, and 
allowing the release of tissue specific antigens (Birk, Elias, et al., 1996). Expression of 
Hsp60 in β-cell may also be augmented by environmental tissue-specific trigger such as viral 
infection via γ-interferon, thus causing β-cell to be targets for anti-Hsp60 T-cells (Birk, Elias, 
et al., 1996).  
Thus what is the purpose and what can the immune system gain from recognising Hsp60? 
Hsp60 is a highly conserved protein, therefore  both bacterial (foreign) and endogenous 
Hsp60 (self) can act as an antigen for B cells (Kaufmann, 1989). At first, production of 
antibodies against Hsp60 was thought to be a mechanism to fight bacterial infection or 
vaccination (Kaufmann, 1989), however it was subsequently found that autoantibodies 
against self-Hsp60 was also found to be associated for various autoimmune diseases such 
as Type 1 Diabetes (F. J. Quintana & Cohen, 2011).  
Various studies with human patients have shown that treatment of Type 1 diabetes with 
p277 epitope can preserve part of the endogenous insulin production by arresting the 
destruction of the β-cell mass in the pancreas (Huurman et al., 2008; Stuart et al., 2012), 
The paper by Stuart et al., 2012 states that a number of Hsp60 peptide epitopes that can 
bind multiple allelic variants of the human major histocompatibility complex molecule HLA-
DR called pan-DR epitopes which can induce low peptide-specific proliferative responses 
and peptide specific production of intracellular cytokines such as interleukin-10 (IL-10) an 
anti-inflammatory cytokine, and interferon- γ (IFN-γ) in type 1 diabetes (Stuart et al., 2012). 
This suggests that Hsp60 and peptides derived from the full length molecule can induce both 
pro-inflammatory and anti-inflammatory cytokines. This confirms Hsp60 as an important 
modulator of inflammation in Type 1 Diabetes Mellitus. It should be noted that Hsp60 is also 
thought to down-regulate inflammation via activated effector T cells up-regulating Hsp60 and 
presenting their own Hsp60 epitopes to anti-ergotypic regulatory T cells (Francisco J. 
Quintana, Mimran, Carmi, Mor, & Cohen, 2008) 
Evidence is also accumulating which seem to suggest that Hsp60 may also be involved in 
the pathogenesis of Type 2 Diabetes Mellitus. A number of studies have shown elevated 
levels of Hsp60 protein in systemic circulation in Type 2 diabetes patients. Yuan et al. (2011) 
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reported the elevated presence of Hsp60 in both serum and saliva of Type 2 diabetics 
compared to a non-diabetic control subjects. Salivary Hsp60 were found to be fourfold higher 
in type 2 diabetics compared to non-diabetics, and serum Hsp60 was found to be 16 fold 
higher than the salivary Hsp60 in Type 2 diabetics. The presence of Hsp60 as a molecular 
marker that represents mitochondrial stress opens up the opportunity for a non-invasive 
diagnostic route to further investigate the relationship of Hsp60 and diabetes (J. Yuan, P. 
Dunn, & R. D. Martinus, 2011). Evidence has been documented which show that when 
human HeLa cells are grown in the presence of mitochondrial inhibitors (such as sodium 
azide, hydrogen peroxide and high glucose) there is a significant up-regulation of Hsp60 at 
the protein level (Hall & Martinus, 2013). This suggests that the increased level of serum 
Hsp60 detected in Type 2 Diabetes Mellitus patients might also be due to mitochondrial 
stress.   
 
Hsp60 & Inflammation 
A number of studies suggest that extracellular Hsp60 play a role as a cellular “danger” signal 
for cellular and humoral immune reactions (Calderwood, Mambula, Gray Jr, & Theriault, 
2007; de Haan, Smeets, Pasterkamp, & Arslan, 2013). In 1997, a hypothesis was proposed 
suggesting that elevated acute-phase/ stress reactants (such as Hsp60) and their major 
cytokine are associated with Type 2 Diabetes (Pickup, Mattock, Chusney, & Burt, 1997). 
Since then, many studies have been conducted looking at circulating markers of 
inflammation, and their association with Type 2 Diabetes Mellitus (Pickup, 2004). 
Inflammation has been found to be an important causative factor in the pathogenesis of  
Type 2 Diabetes and insulin resistance (Wellen & Hotamisligil, 2005). There is also an 
observable association between the pathogenesis of insulin resistance, diabetes and 
atherosclerosis, and the activation of innate immune system by toll-like receptors (TLRs) 
(Curtiss & Tobias, 2009; Shi et al., 2006; Wong & Wen, 2008). Interestingly, a link between 
TLR2 and TLR4 polymorphisms and Type 2 diabetes has been documented, suggesting that 
TLRs may play a causative role in diabetes (Bagarolli, Saad, & Saad, 2010; Gülden & Wen, 
2014). Other studies have shown the increase expression of TLR2 and TLR4 in conventional 
insulin resistance target tissues like skeletal muscle and adipose tissue of Type 2 diabetics 
(Creely et al., 2007; Reyna et al., 2008).  
TLRs are a family of protein that senses the invasion of microorganism. This in turn 
stimulates the TLRs and initiates a range of host defence mechanisms (Takeda, Kaisho, & 
Akira, 2003). Each member of the TLR family are set to recognise a specific pathogen 
component, and when activated it will create a signalling cascade that ultimately leads to the 
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production of cytokine (such as; IL-1β, IL-6, IL-8, (monocyte chemoattractant protein-1 
(MCP-1), and tumour necrosis factor-α (TNF-α)) and adaptive immune response (Takeda et 
al., 2003). Ligands for TLR2 and TLR4 includes; Hsp60, Hsp70, high mobility group B1 
protein, endotoxin, hyaluronan, advance glycation end products and extracellular matrix 
components (Tsan & Gao, 2004). In 2009, it was postulated that the effects of Hsp60 on the 
innate immune system may be due to the presence of bacterial contaminants (LPS, 
lipopolysaccharide, a major cell wall component of gram negative bacteria) in preparations of 
the recombinant mammalian Hsp60 preparations (Tsan & Gao, 2009), however it is now 
clear that activation of innate immune receptors can be caused by Hsp60 on its own and not 
by associated contaminants (Henderson et al., 2010). A study done in 2010 by Dasu et al. 
confirmed that expression of TLR2 and TLR4 in Type 2 diabetics is greatly increased when 
compared to non-diabetics. Furthermore, due to the increase of TLR2 and TLR4 expression, 
there was a subsequent increase of inflammation, which was mediated by nuclear factor 
Kappa Beta (NF-κB) p65 (Dasu, Devaraj, Park, & Jialal, 2010). The concentrations of pro-
inflammatory mediators; IL-1β, IL-6, IL-8, MCP-1, and TNF-α in the serum was also found to 
be significantly increased in Type 2 diabetics, compared to non-diabetics. This novel finding 
suggests that Hsp60 could be playing modulatory responses in inflammation, a metabolic 
characteristic of Type 2 diabetes, through the activation of TLRs.  
Interestingly, anti-human Hsp60 small-hairpin RNAs (shRNAs) has been documented to 
down-regulate the expression of endogenous Hsp60 mRNA 48 hours post-transfection in 
human cells (Corydon, Hansen, Bross, & Jensen, 2005). The study proves that Hsp60 can 
be regulated using RNAi and opens the possibility to develop RNAi based therapeutic 
strategies to treat Type 2 diabetes clinically.  
Many studies has also shown that people suffering from Type 1 and Type 2 diabetes have 
accelerated atherosclerosis and are in greater risk of developing atherosclerosis (Matheus et 
al., 2013). Atherosclerosis is a disease where plaque builds up inside the arteries, and is the 
cause of a majority of cardiovascular diseases (Tabas, García-Cardeña, & Owens, 2015). 
Early atherosclerosis is characterised by the penetration of agranulocyte or mononuclear 
cells, in particular monocytes, macrophages and T-lymphocytes (Xu, Oberhuber, 
Gruschwitz, & Wick, 1990). In the late atherosclerosis lesions, T-lymphocytes were seen to 
be activated, and a substantial proportion of the cells are thought to be reacting against 
Hsp60 (Benagiano et al., 2005; Curry, Portig, Goodall, Kirkpatrick, & Gaston, 2000). A study 
done using rabbits immunised with mycobacterial Hsp60 have shown that atherosclerotic 
lesions can be prevented when the rabbit’s T-lymphocytes are depleted (Metzler et al., 1999; 
Xu et al., 1992). On the other hand, when LDL-receptor deficient mice are introduced to the 
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Hsp60 reactive T-lymphocytes, the mice were able to induce a pronounced atherosclerotic 
vessel wall changes (George, Afek, Gilburd, Shoenfeld, & Harats, 2001).  
A study done in 2007, found a correlation between atherosclerosis and T-cell reactivity to 
Hsp60 in young males but not in men aged 50 and above. This suggests that the T-cell 
reactivity to Hsp60 is more prominent in young and very early stages of arteriosclerosis 
(Knoflach et al., 2007). It is thought that T-cell reactivity to Hsp60 is less prominent in men 
age 50 and over because the majority of the T-cells has already formed from blood to the 
site of inflammation in atherosclerotic plaques and lymphocytes from peripheral blood may 
no longer present the specific antigen repertoire of cells in vessel walls (Knoflach et al., 
2007). This T-cell reactivity to Hsp60 is capable of triggering both innate and adaptive 
immune responses that initiate the earliest inflammatory stage of atherosclerosis, and 
mitochondrial Hsp60 is increasing being recognised as a key autoantigen at the sites of 
endothelial inflammation (Grundtman, Kreutmayer, Almanzar, Wick, & Wick, 2011; Wick, 
2016). However, the mechanisms leading to expression of Hsp60 during the initiation of 
arteriosclerosis due to T-cell reactivity to Hsp60 is still not well understood.  
 
Conclusion 
There is a clear association between Hsp60 and Type 1 and Type 2 diabetes. In Type 1 
diabetes, Hsp60 protein are able to induce the production of anti-Hsp60 antibodies as a 
defence mechanism against pathogens, anti-Hsp60 antibodies also targets endogenous 
Hsp60 (p277 epitope), and results in the destruction of β-islet cells. However, both Hsp60 
and p277 peptide can also prevent β-cell destruction by up-regulation of the anti-
inflammatory Th2 cytokine pathway. Since the loss of β-islet cells is primarily thought to be 
driven by a pro-inflammatory Th1 cytokine response, the shift of Th1 to Th2 by Hsp60 and 
p277 may be involved in attenuation of Type 1 Diabetes Mellitus (Figure 1). The high levels 
of Hsp60 found in the serum in Type 2 diabetic may also lead to the initiation of pro-
inflammatory cytokines in target cells (such as vascular endothelial cells) by interacting with 
TLR2 and TLR4 receptors (Figure 2). Thus, Hsp60 acting as a pro-inflammatory signalling 
molecule may play a role in the non-resolved vascular inflammation, which is increasingly 
being recognised as a feature of Type 2 diabetes. Suggesting that, Hsp60 does indeed play 
a key regulatory role in modulating inflammatory processes in Diabetes Mellitus and could 
also provide a key link between mitochondrial stress and inflammation in Diabetes Mellitus. 
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